Cargando…

Review of Azithromycin Ophthalmic 1% Solution (AzaSite(®)) for the Treatment of Ocular Infections

AzaSite(®) (azithromomycin 1.0%) ophthalmic solution was approved in 2007 by the US Food and Drug Administration (FDA) as the first commercially available formulation of ophthalmic azithromycin for the treatment of bacterial conjunctivitis. AzaSite(®) utilizes a vehicle delivery system called DuraSi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Opitz, Dominick L., Harthan, Jennifer S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619494/ https://www.ncbi.nlm.nih.gov/pubmed/23650453 http://dx.doi.org/10.4137/OED.S7791

Ejemplares similares

Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (AzaSite(®)) solution in the treatment of ocular infections
por: Utine, Canan Asli
Publicado: (2011)

Diagnosis and treatment of anterior uveitis: optometric management
por: Harthan, Jennifer S, et al.
Publicado: (2016)

Demodex blepharitis: clinical perspectives
por: Fromstein, Stephanie R, et al.
Publicado: (2018)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee, Daniel, et al.
Publicado: (2017)

Post-Marketing Surveillance of Levofloxacin 0.5% Ophthalmic Solution for External Ocular Infections
por: Kanda, Yoshiko, et al.
Publicado: (2012)

Therapeutic uses of scleral contact lenses for ocular surface disease: patient selection and special considerations
por: Harthan, Jennifer S, et al.
Publicado: (2018)

Ophthalmic Solutions with a Broad Antiviral Action: Evaluation of Their Potential against Ocular Herpetic Infections
por: Zannella, Carla, et al.
Publicado: (2022)

Ion-activated In Situ Gelling Ophthalmic Delivery Systems of Azithromycin
por: Vijaya, C., et al.
Publicado: (2011)

Cyclodextrin Derivative Enhances the Ophthalmic Delivery of Poorly Soluble Azithromycin
por: Thakur, Anil, et al.
Publicado: (2022)

Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections
por: Miller, Darlene
Publicado: (2008)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee, Afshin, et al.
Publicado: (2013)

Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence
por: Rajpal, Rajesh K, et al.
Publicado: (2014)

Azithromycin in DuraSite(®) for the treatment of blepharitis
por: Luchs, Jodi
Publicado: (2010)

Clinical Ocular Exposure Extrapolation for Ophthalmic Solutions Using PBPK Modeling and Simulation
por: Le Merdy, Maxime, et al.
Publicado: (2022)

Antibiotic resistance in ocular bacterial infections: an integrative review of ophthalmic chloramphenicol
por: Bale, Babatunde Ismail, et al.
Publicado: (2023)

Clinical development of 1% azithromycin in DuraSite(®), a topical azalide anti-infective for ocular surface therapy
por: Friedlaender, Mitchell H, et al.
Publicado: (2007)

A novel fixed-combination timolol-netarsudil-latanoprost ophthalmic solution for the treatment of glaucoma and ocular hypertension
por: Wang, Tao, et al.
Publicado: (2022)

Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Efficacy of azithromycin 1% and 1.5% ophthalmic solutions compared to tobramycin 0.3% eye drops: A systematic review and meta-analysis
por: Alemu, Birhanu Motbaynor, et al.
Publicado: (2020)

Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution
por: Cho, Hyung, et al.
Publicado: (2009)

Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
por: Walimbe, Tejaswini, et al.
Publicado: (2016)

Effect of Diquafosol Ophthalmic Solution on Airflow-Induced Ocular Surface Disorder in Diabetic Rats
por: Dota, Atsuyoshi, et al.
Publicado: (2020)

Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Pharmacokinetics of Azithromycin, Levofloxacin, and Ofloxacin in Rabbit Extraocular Tissues After Ophthalmic Administration
por: Sakai, Tatsuya, et al.
Publicado: (2019)

Optimization of the Ocular Surface Through Treatment of Ocular Surface Disease Before Ophthalmic Surgery: A Narrative Review
por: Schechter, Barry, et al.
Publicado: (2022)

Allergy to ophthalmic solutions
por: Lapeere, Hilde, et al.
Publicado: (2014)

Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial
por: McLaurin, Eugene, et al.
Publicado: (2018)

Comparative study of the ocular efficacy and safety of diclofenac sodium (0.1%) ophthalmic solution with that of ketorolac tromethamine (0.5%) ophthalmic solution in patients with acute seasonal allergic conjunctivitis
por: Dehar, Navdeep, et al.
Publicado: (2012)

Azithromycin novel drug delivery system for ocular application
por: Gilhotra, Ritu Mehra, et al.
Publicado: (2011)

Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open‐angle glaucoma and ocular hypertension
por: Fingeret, Murray, et al.
Publicado: (2019)

The ocular distribution of (14)C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model
por: Baklayan, George A, et al.
Publicado: (2014)

Effect of Solution pH on Distribution of Ophthalmically Administered Brimonidine in Posterior Ocular Tissues in Pigmented Rabbits
por: Shinno, Keisuke, et al.
Publicado: (2019)

Covid-19, ocular manifestation and ophthalmic risks
por: Joob, B., et al.
Publicado: (2020)

Ocular Surface Changes Associated with Ophthalmic Surgery
por: Mikalauskiene, Lina, et al.
Publicado: (2021)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
por: Karpecki, Paul, et al.
Publicado: (2023)

A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis
por: Abelson, Mark, et al.
Publicado: (2007)

Journal of Ophthalmic Inflammation and Infection: why a new journal on ocular inflammation?
por: Rao, Narsing A.
Publicado: (2010)

Ocular Manifestations in Hemodialysis Patients: Importance of Ophthalmic Examination in Prevention of Ocular Sequels
por: Kianersi, Farzan, et al.
Publicado: (2019)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen, Jie, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lg40pl4d0fmt3muvf5m0gljksi